Rhinovirus Infection Clinical Trial
Official title:
Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial
The study will investigate the efficacy and safety of subcutaneous interferon alpha -2a to
eradicate rhinovirus in patients with primary hypogammaglobulinemia. Patients with
hypogammaglobulinemia have persistent rhinovirus infections. Rhinovirus may worsen pulmonary
complications. Pegylated interferon alpha with ribavirin appear to effectively clear
persistent rhinovirus infections in hypogammaglobulinemia patients.
Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection
will be randomly assigned in a double-blind fashion to receive either
- Group 1: subcutaneous pIFNα2a
- Group 2: subcutaneous placebo Subjects will have scheduled study visits at 1-week and
at 2-month after entry to study. In addition, possible bacterial infections will be
treated with antibiotics. Each patient will be followed with weekly nasal surveillance
samples for 2 months and a symptom diary. Blood draws take place at study entry, 1-week
and 2-month time-points.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 |